Asia Pacific Anti-inflammatory Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Biologics, NSAIDs, Corticosteroids, and Others), By Indication (Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Asia Pacific Anti-inflammatory Therapeutics Market Insights, Industry Trend, Forecasts to 2035

Asia Pacific Anti-inflammatory Therapeutics Market Insights Forecasts to 2035

• The Asia Pacific Anti-inflammatory Therapeutics Market Size was estimated at USD 26.4 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.34% from 2025 to 2035
• The Asia Pacific Anti-inflammatory Therapeutics Market Size is Expected to Reach USD 46.8 Billion by 2035

The Asia Pacific Anti-inflammatory Therapeutics Market is anticipated to reach USD 46.8 billion by 2035, growing at a CAGR of 5.34% from 2025 to 2035. The growing prevalence of inflammatory disease as well as technological advancements in drug delivery systems, are driving the anti-inflammatory therapeutics market in the Asia Pacific region.

Market Overview

The Asia Pacific anti-inflammatory therapeutics market refers to the development, manufacturing, and sale of drugs and therapies designed for reducing or eliminating inflammation in the body. Anti-inflammatory therapeutics encompass steroidal and non-steroidal drugs and are often employed to treat a variety of inflammatory disorders. The anti-inflammatory therapeutics market is primarily driven by the alarming rise in autoimmune & respiratory disease incidence, along with the development of novel therapies and rapid uptake of anti-inflammatory medications. There is an upsurging emphasis on stem cell therapy that aids in modulating the immune response, which potentially reduces the need for continuous drug treatment. Further, digital health & remote monitoring that revolutionize disease management offer real-time monitoring of disease progression are enhancing the overall management of chronic inflammatory diseases. An introduction to innovative anti-inflammatory medications, along with the development of targeted biologic therapies, is escalating the market growth opportunity for anti-inflammatory therapeutics.

Report Coverage

This research report categorizes the market for the Asia Pacific anti-inflammatory therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific anti-inflammatory therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific anti-inflammatory therapeutics market.

Driving Factors

An increasing prevalence of chronic, lifestyle-related disorders, respiratory, and infectious illnesses is the factor responsible for driving the anti-inflammatory therapeutics market. The development of anti-inflammatory biologics, which are more efficient than conventional pharmaceuticals, is propelling the market growth for anti-inflammatory therapeutics. Additionally, the technological advancements in anti-inflammatory therapeutics, including nanotechnology drug delivery, enzyme engineering for enhanced efficiency, and advanced imaging techniques for precise diagnosis and monitoring, are promoting the market growth.

Restraining Factors

The side effects and safety concerns associated with anti-inflammatory therapeutic drugs, especially NSAIDs and corticosteroids, are challenging the anti-inflammatory therapeutics market. Further, the stringent regulatory approval processes and high cost of drug development & production are restraining the market growth.

Market Segmentation

The Asia Pacific anti-inflammatory therapeutics market share is classified into drug class, indication, and distribution channel.

• The biologics segment dominated the anti-inflammatory therapeutics market with the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific anti-inflammatory therapeutics market is segmented by drug class into biologics, NSAIDs, corticosteroids, and others. Among these, the biologics segment dominated the anti-inflammatory therapeutics market with the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. Biologics, including disease-modifying antirheumatic drugs (DMARDs), are used for treating rheumatoid arthritis by targeting specific molecules involved in the inflammation process. The effectiveness of biologics for treating chronic inflammatory conditions, along with an increasing prevalence of autoimmune disorders and new biological therapies approvals, is responsible for driving the market in the biologics segment.

• The arthritis segment dominated the market with the largest revenue share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

The Asia Pacific anti-inflammatory therapeutics market is segmented by indication into arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease, and others. Among these, the arthritis segment dominated the market with the largest revenue share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Anti-inflammatory therapeutics in arthritis aim to reduce pain and inflammation. It includes NSAIDs, corticosteroids, and DMARDs. An increasing prevalence of arthritis, with anti-inflammatory drug effectiveness are factor augmenting the anti-inflammatory therapeutics market.  

• The drug stores & retail pharmacies segment accounted for the largest revenue share in 2024 and is anticipated to grow at a significant CAGR during the projected period.

The Asia Pacific anti-inflammatory therapeutics market is segmented by distribution channel into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Among these, the drug stores & retail pharmacies segment accounted for the largest revenue share in 2024 and is anticipated to grow at a significant CAGR during the projected period. Over-the-counter NSAIDs are easily accessible in drug stores and retail pharmacies. Consumer emphasizing self-care and the emergence of pharmacy integration in healthcare networks are the factors that are driving the market in the drug stores & retail pharmacies segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific anti-inflammatory therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• AstraZeneca PLC
• Bayer AG
• Johnson and Johnson
• Novartis AG
• Amgen Inc.
• Pfizer Inc.
• AbbVie Inc.
• GlaxoSmithKline Plc.
• Others

Recent Developments:

• In February 2023, AbbVie released a new subcutaneous auto-doser version of its IL-23 inhibitor Skyrizi (risankizumab) in Japan for the maintenance treatment of moderately to severely active Crohn’s disease inadequately controlled with existing therapies.

• In January 2023, AbbVie launched a new 600 mg intravenous drip infusion version of its IL-23 inhibitor Skyrizi (risankizumab) in Japan for the treatment of moderately to severely active Crohn’s disease inadequately controlled with existing therapies.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific Anti-inflammatory Therapeutics Market based on the below-mentioned segments:

Asia Pacific Anti-inflammatory Therapeutics Market, By Drug Class

• Biologics
• NSAIDs
• Corticosteroids
• Others

Asia Pacific Anti-inflammatory Therapeutics Market, By Indication

• Arthritis
• Respiratory Diseases
• Multiple Sclerosis
• Psoriasis
• Inflammatory Bowel Disease
• Others

Asia Pacific Anti-inflammatory Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies